Development of Farnesyltransferase Inhibitors for Clinical Cancer Therapy: Focus on Hematologic Malignancies

ISSN： 0735-7907

Source： Cancer Investigation, Vol.25, Iss.6, 2007-09, pp. : 484-494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

By Karp Judith E Lancet Jeffrey E

Future Oncology, Vol. 1, Iss. 6, 2005-12 ,pp. : 719-731

Future Medicine

Access to resources Recommend Favorite

Pre-clinical development of farnesyltransferase inhibitors

By Lobell R.B. Kohl N.E.

Cancer and Metastasis Reviews, Vol. 17, Iss. 2, 1998-06 ,pp. : 203-210

Springer Publishing Company

Access to resources Recommend Favorite

New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies

By Pimentel Agustin Velez Michel Barahona Luz J Swords Ronan Lekakis Lazaros

Future Oncology, Vol. 9, Iss. 5, 2013-05 ,pp. : 681-697

Future Medicine

Access to resources Recommend Favorite

HEMATOLOGIC MALIGNANCIES

Cancer Investigation, Vol. 25, Iss. 1, 2007-01 ,pp. : 33-47

Informa Healthcare

Access to resources Recommend Favorite

Current status of molecular targeted therapy for hematologic malignancies: introduction

By Ueda Takanori

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 1-2

Springer Publishing Company

Access to resources Recommend Favorite